不整脈(Arrhythmias):治療薬のグローバルパイプライン動向(2014年下半期)

◆英語タイトル:Arrhythmias - Pipeline Review, H2 2014
◆商品コード:GMDHC5496IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年9月15日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Arrhythmias – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Arrhythmias – Pipeline Review, H2 2014’, provides an overview of the Arrhythmias’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arrhythmias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arrhythmias and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arrhythmias
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Arrhythmias and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Arrhythmias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Arrhythmias pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Arrhythmias
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Arrhythmias pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Arrhythmias Overview 6
Therapeutics Development 7
Pipeline Products for Arrhythmias – Overview 7
Pipeline Products for Arrhythmias – Comparative Analysis 8
Arrhythmias – Therapeutics under Development by Companies 9
Arrhythmias – Therapeutics under Investigation by Universities/Institutes 10
Arrhythmias – Pipeline Products Glance 11
Early Stage Products 11
Arrhythmias – Products under Development by Companies 12
Arrhythmias – Products under Investigation by Universities/Institutes 13
Arrhythmias – Companies Involved in Therapeutics Development 14
Gilead Sciences, Inc. 14
Orion Oyj 15
SciFluor Life Sciences, LLC 16
Nyken BV 17
Arrhythmias – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Molecule Type 23
Drug Profiles 25
F-15845 – Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
NYK-1112 – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GS-967 – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules For Arrhythmia – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Antagonize Ryanodine Receptor for Cardiac Arrhythmias – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ORM-10103 – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
KN-93 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
PP-1 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit Vesicular Acetylcholine Transporter for Arrhythmias – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Arrhythmias – Dormant Projects 36
Arrhythmias – Discontinued Products 37
Arrhythmias – Product Development Milestones 38
Featured News & Press Releases 38
Mar 01, 2011: Geron Announces Preclinical Study Data Of GRNCM1 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products under Development for Arrhythmias, H2 2014 7
Number of Products under Development for Arrhythmias - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Arrhythmias - Pipeline by Gilead Sciences, Inc., H2 2014 14
Arrhythmias - Pipeline by Orion Oyj, H2 2014 15
Arrhythmias - Pipeline by SciFluor Life Sciences, LLC, H2 2014 16
Arrhythmias - Pipeline by Nyken BV, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Arrhythmias - Dormant Projects, H2 2014 36
Arrhythmias - Discontinued Products, H2 2014 37

List of Figures
Number of Products under Development for Arrhythmias, H2 2014 7
Number of Products under Development for Arrhythmias - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Top 10 Target, H2 2014 19
Number of Products by Stage and Top 10 Target, H2 2014 20
Number of Products by Top 10 Mechanism of Action, H2 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 22
Number of Products by Top 10 Molecule Type, H2 2014 23
Number of Products by Stage and Top 10 Molecule Type, H2 2014 24

【掲載企業】

Gilead Sciences, Inc.
Orion Oyj
SciFluor Life Sciences, LLC
Nyken BV

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[不整脈(Arrhythmias):治療薬のグローバルパイプライン動向(2014年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆